Want to see HIND full AI Analyst Report?
Vyome Holdings (HIND) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Aug 12, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1The Asset Purchase may not be consummated unless important conditions are satisfied or waived and there can be no assurance that the Asset Sale will be consummated.
The Asset Purchase Agreement contains a number of conditions that must be satisfied or waived (to the extent permitted by applicable law) to consummate the Asset Sale. Those conditions include, among others: - approval of the proposal to sell our assets pursuant to the Asset Purchase Agreement by our stockholders;- satisfaction of conditions regarding the accuracy of representations and warranties and compliance with covenants in the Asset Purchase Agreement; and - the absence of any adverse law or order promulgated, entered, enforced, enacted, or issued by any government entity that prohibits, restrains, or makes illegal the consummation of the Asset Sale or the other transactions contemplated by the Asset Purchase Agreement.
- Corporate Activity and Growth - Risk 2The Merger may not be consummated unless important conditions are satisfied or waived and there can be no assurance that the Merger will be consummated.
The Merger Agreement contains a number of conditions that must be satisfied or waived (to the extent permitted by applicable law) to consummate the Merger. Those conditions include, among others: - approval of the proposal to issue shares of our common stock pursuant to the Merger Agreement and approval of the proposal to sell our assets pursuant to the Asset Purchase Agreement by our stockholders;- approval of the proposal to complete the Merger by Vyome's stockholders;- the absence of any adverse law or order promulgated, entered, enforced, enacted, or issued by any government entity that prohibits, restrains, or makes illegal the consummation of the Merger or the other transactions contemplated by the Merger Agreement;- the effectiveness of a registration statement on Form S-4 under the Securities Act of 1933, as amended, and the absence of any stop order issued by the SEC suspending the use of such registration statement;- the shares of our common stock to be issued in the Merger being approved for listing on The Nasdaq Capital Market and approval of the combined company's continued listing on The Nasdaq Capital Market;- subject to certain materiality exceptions, the accuracy of certain representations and warranties of each of Vyome and ReShape contained in the Merger Agreement and the compliance by each party with the covenants contained in the Merger Agreement; and - the absence of a material adverse effect with respect to each of Vyome and ReShape. These conditions to the consummation of the Merger may not be satisfied or waived (to the extent permitted by applicable law) and, as a result, the Merger may not be consummated at the time expected, or at all. In addition, we or Vyome may elect to terminate the Merger Agreement in certain other circumstances.
- Corporate Activity and Growth - Risk 3Failure to consummate the Merger could negatively impact our future operations and financial results and our future stock price.
If the Merger is not consummated for any reason, we may be subjected to a number of material risks, including the following: - a decline in the market price of the shares of our common stock to the extent that the current market prices reflect a market assumption that the Merger will be consummated and will be beneficial to the value of our business after the closing date of the Merger;- having to pay certain costs related to the proposed Merger, such as legal, accounting, financial advisory, printing and mailing fees, which must be paid regardless of whether the Merger is consummated;- addressing the consequences of operational decisions made since the signing of the Merger Agreement, including because of restrictions on our operations imposed by the terms of the Merger Agreement and decisions to delay or defer capital expenditures;- returning the focus of management and personnel to operating ReShape on a standalone basis, without any of the benefits expected to have been provided by the consummation of the Merger; and - negative reactions from our stockholders, suppliers, employees, and the medical community. In addition to the above risks, we may be required, under certain circumstances, to pay Vyome a termination fee of $1.0 million, which may materially adversely affect our financial condition. Our business may be adversely impacted by the failure to pursue other beneficial opportunities due to the focus of our management on the Merger. A failure to consummate the Merger may also result in negative publicity, reputational harm, litigation against us or our directors and officers, and a negative impression of ReShape in the financial markets. If the Merger is not consummated, we cannot assure our stockholders that these risks will not materialize and will not materially adversely affect our business, financial results and stock price.
- Corporate Activity and Growth - Risk 4The Merger may disrupt attention of our management from ongoing business operations.
We have expended, and expect to continue to expend, significant management resources to consummate the Merger. The attention of our management may be diverted away from the day-to-day operations of our businesses, including implementing initiatives to improve performance, execution of existing business plans and pursuing other beneficial opportunities, in an effort to consummate the Merger. This diversion of management resources could disrupt our operations and may have an adverse effect on our business, financial conditions, results of operations and cash flows or the combined company after the closing date of the Merger.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 78
- Share Price & Shareholder Rights - Risk 1The trading price of our common stock has been volatile and is likely to be volatile in the future.
The trading price of our common stock has been highly volatile. The market price for our common stock will be affected by a number of factors, including: - the denial or delay of regulatory clearances or approvals of our product or receipt of regulatory approval of competing products;- our ability to accomplish clinical, regulatory and other product development milestones and to do so in accordance with the timing estimates we have publicly announced;- changes in policies affecting third-party coverage and reimbursement in the United States and other countries;- changes in government regulations and standards affecting the medical device industry and our product;- ability of our products to achieve market success;- the performance of third-party contract manufacturers and component suppliers;- our ability to develop sales and marketing capabilities;- actual or anticipated variations in our results of operations or those of our competitors;- announcements of new products, technological innovations or product advancements by us or our competitors;- developments with respect to patents and other intellectual property rights;- sales of common stock or other securities by us or our stockholders in the future;- additions or departures of key scientific or management personnel; - disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;- the trading volume of our common stock;- changes in earnings estimates or recommendations by securities analysts, failure to obtain or maintain analyst coverage of our common stock or our failure to achieve analyst earnings estimates;- public statements by analysts or clinicians regarding their perceptions of our clinical results or the effectiveness of our products;- decreases in market valuations of medical device companies; and - general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors. The stock prices of many companies in the medical device industry have experienced wide fluctuations that have often been unrelated to the operating performance of these companies. Following periods of volatility in the market price of a company's securities, securities class action litigation often has been initiated against a company. If class action litigation is initiated against us, we may incur substantial costs and our management's attention may be diverted from our operations, which could significantly harm our business.
- Share Price & Shareholder Rights - Risk 2Future sales of a substantial number of shares of our common stock may cause the price of our common stock to decline.
If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our shares of common stock after the closing of the Merger, the trading price of our shares of common stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Certain of our shareholders are subject to lock-up provisions that restrict their ability to transfer shares of our common stock or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security convertible into or exercisable or exchanged for the Company until 360 days from the date of Closing of the Merger, provided that 20% of the shares subject to the lock-up will be released from the restrictions in the lock-up agreement on the 91st day after the closing and the remainder will be released from the restrictions in equal increments every 30 days thereafter.
- Share Price & Shareholder Rights - Risk 3If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our shares, our share price and trading volume could decline.
The trading market for shares of our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts commence coverage of the Company, the trading price for its shares would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issues an adverse opinion regarding us, our business model, our intellectual property or our share performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our share price would likely decline. If one or more of these analysts cease coverage or fail to publish reports regularly, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.
- Share Price & Shareholder Rights - Risk 4Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to the Vyome Assets or its product candidates.
We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as shares of our common stock or, alternatively, may have dividend, liquidation or other preferences to shares of our common stock. The issuance of additional equity securities will dilute the holdings of existing shareholders and may reduce the share price of shares of our common stock. In addition, if our board of directors elects to institute new equity incentive plans or increase the number of shares available for future grant under its existing equity incentive plan, stockholders may experience additional dilution, which could cause our stock price to fall. Pursuant to certain Registration Rights Agreements entered into in connection with the Merger, certain shareholders of Vyome can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering such securities and certain of its other securities. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Lock-Up Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in the public market may have an adverse effect on the market price of the our securities. If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to the Vyome Assets or any product candidates, or grant licenses on terms unfavorable to us. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of the Vyome Assets.
- Share Price & Shareholder Rights - Risk 5Our principal shareholders, directors and executive officers own a significant percentage of our capital shares, and also have significant influence over our management.
Our directors, executive officers, holders of 5% or more of our capital shares and their respective affiliates beneficially own, in the aggregate, approximately 74.54% of our outstanding voting shares as of December 31, 2025. For a detailed discussion, see "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters". This concentration of voting power may make it less likely that any other holder of shares of our common stock will be able to affect the way we are managed and could delay or prevent an acquisition of us on terms that other shareholders may desire. This could prevent transactions in which shareholders might otherwise recover a premium for their shares over current market prices. Further, under the Merger Agreement, KKG Enterprises, LLC (an entity under the control of Krishna K. Gupta, who serves as Chairman of our board of directors) and Shiladitya Sengupta, each have a right to appoint 2 (two) directors on our board of directors, which in total comprises 6 (six) members. Accordingly, the aforesaid individuals will have control over the appointment of a majority of directors on our board of directors, and are directly or indirectly able to affect the decisions of the board, and, through their recommendations, of our shareholders.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.
